IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. (Q54584786)

1 June 2018

title

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. (English)

1 reference

1 June 2018

1 reference

Marta Mellai

1

1 reference

1 June 2018

Angela Piazzi

2

1 reference

1 June 2018

Valentina Caldera

3

1 reference

1 June 2018

Oriana Monzeglio

4

1 reference

1 June 2018

Paola Cassoni

5

1 reference

1 June 2018

Guido Valente

6

1 reference

1 June 2018

Davide Schiffer

7

1 reference

1 June 2018

publication date

4 June 2011

1 reference

1 June 2018

Journal of Neuro-Oncology

published in

1 reference

1 June 2018

volume

105

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

page(s)

345-357

1 reference

1 June 2018

An integrated genomic analysis of human glioblastoma multiforme

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH mutations in glioma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Molecular Classification of Low-Grade Diffuse Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Cyclin D1 expression in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Cyclin D1 expression in normal oligodendroglia and microglia cells: its use in the differential diagnosis of oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Gliomagenesis and neural stem cells: Key role of hypoxia and concept of tumor "neo-niche".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0596-3

Molecular signatures classify astrocytic gliomas by IDH1 mutation status.

21 January 2018

1 reference

12 December 2020

Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase.

1 reference

12 December 2020

High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.

1 reference

12 December 2020

Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3.

1 reference

12 December 2020

Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.

1 reference

12 December 2020

MGMT promoter hypermethylation in a series of 104 glioblastomas

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1007/S11060-011-0596-3

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018